These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Zhu R; Shang Y; Chen S; Xiao H; Ren R; Wang F; Xue Y; Li L; Li Y; Chu N; Huang H Microbiol Spectr; 2022 Dec; 10(6):e0137222. PubMed ID: 36250885 [TBL] [Abstract][Full Text] [Related]
5. Yu X; Gao X; Li C; Luo J; Wen S; Zhang T; Ma Y; Dong L; Wang F; Huang H Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138571 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. Aguilar-Ayala DA; Cnockaert M; André E; Andries K; Gonzalez-Y-Merchand JA; Vandamme P; Palomino JC; Martin A J Med Microbiol; 2017 Aug; 66(8):1140-1143. PubMed ID: 28749330 [TBL] [Abstract][Full Text] [Related]
7. Sudapyridine (WX-081) antibacterial activity against Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581 [TBL] [Abstract][Full Text] [Related]
8. Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127 [TBL] [Abstract][Full Text] [Related]
9. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report. Erber J; Weidlich S; Tschaikowsky T; Rothe K; Schmid RM; Schneider J; Spinner CD BMC Infect Dis; 2020 May; 20(1):365. PubMed ID: 32448204 [TBL] [Abstract][Full Text] [Related]
11. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients. Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726 [TBL] [Abstract][Full Text] [Related]
12. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology and risk factors associated with NTM pulmonary and extrapulmonary infections in a high tuberculosis endemic Region. Wani SR; Wattal C; Raveendran R Indian J Med Microbiol; 2020; 38(2):169-175. PubMed ID: 32883930 [TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study. Kurosawa K; Rossenu S; Biewenga J; Ouwerkerk-Mahadevan S; Willems W; Ernault E; Kambili C J Clin Pharmacol; 2021 Oct; 61(10):1344-1355. PubMed ID: 33991350 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Zheng L; Qi X; Zhang W; Wang H; Fu L; Wang B; Chen X; Chen X; Lu Y Front Cell Infect Microbiol; 2023; 13():1115530. PubMed ID: 37077530 [TBL] [Abstract][Full Text] [Related]
16. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV. Gil E; Sweeney N; Barrett V; Morris-Jones S; Miller RF; Johnston VJ; Brown M Emerg Infect Dis; 2021 Mar; 27(3):944-948. PubMed ID: 33622490 [TBL] [Abstract][Full Text] [Related]
17. High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo. Ragunathan P; Sae-Lao P; Hamela C; Alcaraz M; Krah A; Poh WH; Ern Pee CJ; Hou Lim AY; Rice SA; Pethe K; Bond PJ; Dick T; Kremer L; Bates RW; Grüber G J Biol Chem; 2024 Feb; 300(2):105618. PubMed ID: 38176652 [TBL] [Abstract][Full Text] [Related]
18. Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages. Viljoen A; Raynaud C; Johansen MD; Roquet-Banères F; Herrmann JL; Daher W; Kremer L Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209005 [TBL] [Abstract][Full Text] [Related]
19. Non-tuberculous mycobacteria disease pre-lung transplantation: A systematic review of the treatment regimens and duration pre- and post-transplant. van Gemert JP; Ravensbergen SJ; Verschuuren EAM; Kerstjens HAM; Willemse BWM; van Ingen J; Hoefsloot W; Gan T; Akkerman OW Transplant Rev (Orlando); 2023 Dec; 37(4):100800. PubMed ID: 37832509 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract. He G; Wu L; Zheng Q; Jiang X Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867 [No Abstract] [Full Text] [Related] [Next] [New Search]